Genetic products company, Affymetrix Inc. (AFFX), inked a ‘Powered by Affymetrix’ (“PbA”) Program agreement with Korea-based biotechnology company, DNA Link Inc. Following the terms of the deal, DNA ...

Affymetrix Inc. has announced the publication of the MicroArray Quality Control (MAQC) study, a collaborative effort led by the FDA that included 137 scientists from private and public sector ...

Affymetrix Inc. and Partners HealthCare have announced that they have entered into a three-year translational research collaboration to develop microarray-based diagnostics for complex diseases such ...

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to ...

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

Epigenomics and Affymetrix announced that Affymetrix has granted Epigenomics non-exclusive access to Affymetrix microarray technology to develop and market microarray-based in vitro diagnostic tests ...

Affymetrix Inc. announced that the US Food and Drug Administration (FDA) has granted regulatory clearance to its GCS3000Dx (GCSDx) platform for in vitro gene expression diagnostic testing. The ...

VICTORIA, BC, Sept. 5 /PRNewswire/ - GenoLogics, a leading developer oflab and data management software solutions for life sciences research,announced today the Company has joined the Affymetrix ...

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Richard Shippy has joined the company as its Chief Business Officer. Richard was one of the ...

An English Court of Appeals decision in November held that Affymetrix (Santa Clara, CA) has a valid license to critical DNA microarray technology developed by Oxford Gene Technology (OGT; Oxford, UK).

System and TRANSFAC(R) database has achieved GeneChip-compatible(TM) status with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip(R) microarray platform. As a GeneChip-compatible software provider, BIOBASE ...